Despite initially missing the pre-specified primary endpoint (OS in the intention-to-treat cohort) the Keynote-040 trial led to the FDA approval (2016) of pembrolizumab for R/M SCCHN patients with a PD-L1 TPS of ≥50% after prior platinum-based therapy. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.